Pembrolizumab is an immune checkpoint inhibitor and inhibits tumor progression by down-regulating the PDL1/PD1 pathway, confirming the importance of blocking the PD-1 pathway using antibodies to immune blocking proteins in cancer treatment [40]. The gene discussed is CD274; the disease is neoplasm.